



“Molecular Design, Radiolabeling and Biological Evaluation of Some Anticancer Drugs for Certain Nuclear Medicine Applications”

Thesis Presented by

Noha Anwer Bayoumi Mostafa

BSc. In Pharmaceutical Science- 2003

M.Sc. In Pharmaceutical Sciences (Pharmaceutical Chemistry)- 2009

Assistant Lecture in Hot labs center

Egyptian Atomic Energy Authority

Submitted for the partial fulfillment of the

Doctorate of philosophy Degree

In Pharmaceutical Sciences(Pharmaceutical Chemistry)

Under the supervision of

Prof. Dr. Khaled Abouzid Mohamed

Professor and head of Pharmaceutical Chemistry
department, Faculty of

Pharmacy-Ain Shams University

Prof. Dr. Mohamed Taha Hussein El-kolaly

Professor of Radiopharmaceutics&

Ex. Chairman of Egyptian Atomic Energy

Authority

Prof. Dr. Abeer Mohamed Amin

Professor of Radiochemistry

Hot labs center, Egyptian Atomic
Energy Authority

Ass. Prof. Dr. Nassr Saad Mohamed

Assistant Professor of Pharmaceutical

Chemistry, Faculty of Pharmacy, Ain-Shams
University

Department of Pharmaceutical Chemistry

Faculty of Pharmacy

Ain Shams University

2015

ACKNOWLEDGEMENT

First and foremost thanks to **God** for helping me to fulfill this work. I would like to express my deep gratitude and appreciation to **Prof. Dr. Mohamed Taha Hussein El-kolally** Professor of Radiopharmaceutics & Ex. Chairman of Egyptian Atomic Energy Authority for his valuable supervision, support, continuous scientific advice, encouragement and careful revision of this work.

I am profoundly grateful to **Prof. Dr. Khaled Abouzid Mohamed** Professor of Pharmaceutical Chemistry & vice Dean of Faculty of Pharmacy Ain-Shams University for his time, valuable supervision and careful revision of this thesis.

I am sincerely grateful to **Prof. Dr. Abeer Mohamed Amin**, Professor of biochemistry, Labeled Compounds Department, Hot Labs. Center, Egyptian Atomic Energy Authority for suggesting the topic, planning of the experimental work and support.

I am profoundly grateful to **Ass. Prof. Dr. Nassr Saad Mohamed** Assistant Professor of Pharmaceutical Chemistry, Ain-Shams University for his time, great effort in the molecular modeling part of the work and valuable revision.

I would like to express my special thanks to **Prof. Dr. Ahmed Abd El-Mohty** professor of radiochemistry, Isotopes and radioactive generators, Department, Hot Labs. Center, Egyptian Atomic Energy Authority for his continuous valuable advice and encouragement.

I would like also to express my special thanks to **Prof. Dr Mohamed Abd El-Motaleb**, Professor of Radiochemistry, Labeled Compounds Department, Hot Labs. Center, Egyptian Atomic Energy Authority, for his advice and great support during practical work.

I am sincerely grateful to my **father, mother, husband, sister, brother, daughter and the rest of my family** for their great help and continuous support and encouragement.

I am sincerely thankful for my best friends **Ghada Attia, Manal Magdy, Mona Osama and Hassan Medhat** for their great help and encouragement during the practical work of this thesis.

Finally I would like to thank everyone else at the Hot Labs. Center, Atomic Energy Authority, whose names are too numerous to mention for their help in this work.

Content

No.	Title	page
	Aknowledgement	i
	Contents	iii
	List of figures	xi
	List of tables	xv
	List of abbreviations	xxi
	Abstract	xxiii
1	Introduction	1
1.1.	Nuclear medicine.....	1
1.1.1.	Nuclear medicine procedures.....	1
1.1.1.1.	Imaging procedures.....	1
1.1.1.2.	<i>In-vivo</i> function Studies.....	2
1.1.1.3.	<i>In-vitro</i> function studies.....	2
1.1.1.4.	Therapeutic procedures.....	2
1.1.2.	Main nuclear medicine instrumentations	3
1.1.2.1.	Gamma camera	3
1.1.2.2.	Single Photon Emission Computed Tomography	4

	(SPECT).....	
1.1.2.3.	Positron Emission Tomography (PET).....	4
1.2.	Nuclear pharmacy.....	6
1.2.1.	Radiopharmaceuticals	6
1.2.1.1.	Radiopharmaceutical ligands.....	10
1.2.1.2.	Radionuclides	11
1.2.1.2.1.	Sources of radionuclides.....	12
1.2.1.2.1.1.	The reactor.....	12
1.2.1.2.1.2.	The cyclotron.....	13
1.2.1.2.1.3.	The generator.....	14
1.3.	Technetium radiopharmaceuticals.....	15
1.3.1.	Technetium chemistry.....	17
1.3.2.	Methods of ^{99m}Tc labeling	18
1.3.2.1.	Direct labeling method.....	18
1.3.2.2.	Transchelation (ligand exchange) labeling method....	18
1.3.2.3.	Labeling with bifunctional chelating agents.....	19
1.4.	Iodine radiopharmaceuticals.....	20
1.4.1.	Iodine chemistry.....	20

1.4.2.	Iodine radioisotopes.....	21
1.4.2.1	Iodine-123.....	21
1.4.2.2	Iodine-124.....	22
1.4.2.3	<i>Iodine-125</i>	22
1.4.2.4	<i>Iodine-131</i>	23
1.4.3.	Radioiodination methods.....	24
1.4.3.1	Electrophilic substitution.....	24
1.4.3.1.1	Principle of electrophilic substitution.....	25
1.4.3.1.2	Oxidizing agents	25
1.4.3.1.2.1	Iodine monohalide (ICl, IF).....	25
1.4.3.1.2.2	N-Chloroamides	26
1.4.3.1.2.3	Iodogen.....	28
1.4.3.1.2.4	N-Halosuccinimides.....	28
1.4.3.1.2.5	N-Halosuccinimides Peracids	29
1.4.3.1.2.6	Other oxidants.....	30
1.4.3.2	Nucleophilic substitution.....	31
1.4.3.2.1	Halogen exchange.....	31
1.4.3.2.2	Isotopic exchange.....	32

1.4.3.3	Radioiododemetalation.....	33
1.4.3.4	Conjugation labeling.....	33
1.4.3.5.	Addition to double bonds.....	33
1.5.	Cancer.....	34
1.5.1.	Cancer imaging	35
1.5.1.1.	Examples of radiopharmaceuticals for cancer imaging	36
1.5.1.1.1.	Radiolabeled peptides.....	36
1.5.1.1.2.	Radiolabeled antibodies.....	37
1.5.1.1.3.	Thallium-201 chloride ($^{201}\text{TlCl}$).....	38
1.5.1.1.4.	$^{99\text{m}}\text{Tc}$ -Sestamibi.....	39
1.5.1.1.5.	$^{99\text{m}}\text{Tc}$ -tetrofosmin	39
1.5.1.1.6.	$^{131}\text{I}/^{123}\text{I}$ -Metaiodobenzylguanidine (MIBG).....	40
1.5.2.	Cancer therapy.....	41
1.5.2.1	Surgery.....	41
1.5.2.2	Chemotherapy	41
1.5.2.3	Radiotherapy.....	42
1.5.2.4	Immunotherapy and radioimmunotherapy.....	43
1.5.2.5	Targeted radiotherapy.....	44
1.5.2.5.1	Examples of radiopharmaceuticals for cancer therapy	45

1.5.2.5.1.1.	Iodine 131 solution.....	45
1.5.2.5.1.2.	¹³¹ I-Lipiodol®	46
1.5.2.5.1.3.	Radiolabeled anticancer drugs.....	46
2	Research objectives	47
3	Results and discussion	50
3.1.	Molecular modeling and docking study results.....	50
3.1.1.	Results of molecular modeling and docking study of Mitoxantrone and ^{99m} Tc-Mitoxantrone complex.....	53
3.1.2.	Results of molecular modeling and docking study of Mitomycin C and ^{99m} Tc-Mitomycin C complex....	66
3.1.3.	Results of molecular modeling and docking study of Cladribine and iodinated Cladribine	78
3.1.4.	Results of ADMET properties prediction of ^{99m} Tc-Mitoxantrone complex, ^{99m} Tc-Mitomycin C complex and iodinated Cladribine.....	82
3.1.5.	Molecular modeling and docking study conclusion....	85
3.2.	Radiolabeling results.....	86
3.2.1.	Results of Mitoxantrone and Mitomycin C ^{99m} Tc radiolabeling.....	88
3.2.1.1.	Results of determination of Sn (II) by spectrophotometric method.....	88

3.2.1.2.	Optimum conditions for Mitoxantrone and Mitomycin C ^{99m} Tc radiolabeling.....	90
3.2.1.3.	Results of radiochemical analysis of ^{99m} Tc-Mitoxantrone and ^{99m} Tc-Mitomycin C.....	91
3.2.1.3.1.	Results of ascending paper radiochromatograph of ^{99m} Tc-Mitoxantrone and ^{99m} Tc-Mitomycin C	91
3.2.1.3.2.	Results of paper electrophoresis of ^{99m} Tc-Mitoxantrone and ^{99m} Tc-Mitomycin C	93
3.2.1.3.3.	Results of HPLC analysis of ^{99m} Tc-Mitoxantrone and ^{99m} Tc-Mitomycin C.....	94
3.2.1.4.	Factors affecting ^{99m} Tc radiolabeling of Mitoxantrone and Mitomycin C	95
3.2.1.4.1.	Effect of the Mitoxantrone and Mitomycin C concentration.....	95
3.2.1.4.2.	Effect of pH of the reaction mixture	98
3.2.1.4.3.	Effect of Sn (II) concentration.....	100
3.2.1.4.4.	Effect of temperature	103
3.2.1.4.5.	Effect of reaction time	105
3.2.1.5.	<i>In-vitro</i> stability study of ^{99m} Tc-Mitoxantrone and ^{99m} Tc-Mitomycin C.....	108
3.2.1.6.	Partition coefficient of ^{99m} Tc-Mitoxantrone and ^{99m} Tc-Mitomycin C	111

3.2.2.	Results of Cladribine radioiodination	112
3.2.2.1.	Optimum conditions for Cladribine radioiodination	112
3.2.2.2.	Results of radiochemical analysis of radioiodinated Cladribine.....	112
3.2.2.2.1	Results of ascending paper radiochromatography of radioiodinated Cladribine.....	112
3.2.2.2.2	Results of paper electrophoresis of radioiodinated Cladribine	114
3.2.2.2.3	Results of HPLC analysis of radioiodinated Cladribine.....	114
3.2.2.3.	Factors affecting radioiodination of Cladribine.....	115
3.2.2.3.1	Effect of Cladribine concentration	115
3.2.2.3.2	Effect of the oxidizing agent type and concentration	117
3.2.2.3.3	Effect of pH of the reaction mixture.....	119
3.2.2.3.4	Effect of temperature	121
3.2.2.3.5	Effect of reaction time.....	123
3.2.2.4.	<i>In vitro</i> stability study of radioiodinated Cladribine	124
3.2.2.5.	Partition coefficient of radioiodinated Cladribin.....	126
3.2.3.	Radiolabeling conclusion.....	126
3.3.	Biological evaluation results.....	127

3.3.1.	Results of ^{99m}Tc -Mitoxantrone biodistribution study..	128
3.3.2.	Results of ^{99m}Tc -Mitomycin C biodistribution study...	134
3.3.3.	Results of ^{125}I -Cladribine biodistribution study	140
3.3.4.	Biodistribution assay.....	146
3.3.5.	Biodistribution studies conclusion.....	147
4	Final conclusion	148
5	Experimental	151
5.1.	Chemicals.....	151
5.2.	Equipment.....	151
5.3.	Molecular modeling programs.....	153
5.4.	Radioactive material.....	153
5.5.	Animals and carcinoma cell line	153
5.6.	Molecular modeling and docking study.....	153
5.6.1.	Molecular modeling and docking study of Mitoxantrone and ^{99m}Tc -Mitoxantrone complex.....	153
5.6.2.	Molecular modeling and docking study of Mitomycin C and ^{99m}Tc -Mitomycin C complex.....	155
5.6.3.	Molecular modeling and docking study of Cladribine and iodinated Cladribine.....	155

5.6.4.	Method of ADMET properties prediction of ^{99m}Tc -Mitoxantrone complex, ^{99m}Tc -Mitomycin C complex and iodinated Cladribine.....	156
5.7.	Radiolabeling study.....	157
5.7.1.	Preparation of buffers.....	157
5.7.2.	Technetium radiolabeling of Mitoxantrone and Mitomycin C.....	158
5.7.2.1.	Preparation of stock solution of stannous chloride dihydrate $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$	158
5.7.2.2.	Determination of Sn (II) concentration by spectrophotometric method	159
5.7.2.3.	Elution of $^{99m}\text{TcO}_4$ using sterile 0.9 % sodium chloride solution	159
5.7.2.4.	Method of ^{99m}Tc radiolabeling of Mitoxantrone and Mitomycin C	160
5.7.2.5.	Radiochemical analysis of ^{99m}Tc -Mitoxantrone and ^{99m}Tc -Mitomycin C complexes.....	160
5.7.2.5.1	Ascending paper radiochromatography of ^{99m}Tc -Mitoxantrone and ^{99m}Tc -Mitomycin C.....	161
5.7.2.5.2	Paper electrophoresis of ^{99m}Tc -Mitoxantrone and ^{99m}Tc -Mitomycin C	161
5.7.2.5.3	HPLC analysis of ^{99m}Tc -Mitoxantrone and ^{99m}Tc -Mitomycin C	162

5.7.2.6.	Study of the factors affecting percent radiochemical yield of ^{99m}Tc -Mitoxantrone and ^{99m}Tc -Mitomycin C	162
5.7.2.6.1	Effect of ligand concentration	163
5.7.2.6.2	Effect of pH of the reaction mixture	163
5.7.2.6.3	Effect of Sn (II) concentration	163
5.7.2.6.4	Effect of temperature	163
5.7.2.6.5	Effect of reaction time	164
5.7.2.7.	<i>In-vitro</i> stability of ^{99m}Tc -Mitoxantrone and ^{99m}Tc -Mitomycin C	164
5.7.2.7.	Determination of the partition coefficient of ^{99m}Tc -Mitoxantrone and ^{99m}Tc -Mitomycin C complexes.....	164
5.7.3.	Radioiodination of Cladribine.....	165
5.7.3.1.	Method of radioiodination of Cladribine.....	165
5.7.3.2.	Radiochemical analysis of radioiodinated Cladribine	166
5.7.3.2.1.	Ascending paper radiochromatography of radioiodinated Cladribine.....	166
5.7.3.2.2.	Paper electrophoresis of radioiodinated Cladribine...	166
5.7.3.2.3.	HPLC analysis of radioiodinated Cladribine.....	167
5.7.3.3.	Study of the factors affecting percent radiochemical	167

	yield of radioiodinated Cladribine.....	
5.7.3.3.1.	Effect of Cladribine concentration	167
5.7.3.3.2.	Effect of pH of the reaction mixture	168
5.7.3.3.3.	Effect of oxidizing agent type and concentration.....	168
5.7.3.3.4.	Effect of temperature.....	168
5.7.3.3.5.	Effect of reaction time.....	168
5.7.3.4.	<i>In-vitro</i> stability of radioiodinated Cladribine.....	168
5.7.3.5.	Determination of the partition coefficient of ¹²⁵ I- Cladribine	169
5.8.	Biological evaluation study.....	169
5.8.1.	Induction of tumor in mice.....	169
5.8.2.	Biodistribution studies.....	169
6	References	171
7	Arabic summary	

List of figures

Figure No	Title	Page
Figure (1)	Schematic diagram of a gamma camera	3
Figure (2)	SPECT scanner	4
Figure (3)	PET operation process	5
Figure (4)	Schematic diagram of radiopharmaceutical binding to the target	10
Figure (5)	The reactor	13
Figure (6)	The cyclotron	14
Figure (7)	^{99}Mo - $^{99\text{m}}\text{Tc}$ generator system	15
Figure (8)	Chemical structure of some $^{99\text{m}}\text{Tc}$ -labeled complexes	16
Figure (9)	Generation of reactive iodonium species by CAT in acidic and basic medium	27
Figure (10)	Chemical structure of iodogen	28
Figure (11)	Chemical structures of N-chlorosuccinimide and N-bromosuccinimide	29
Figure (12)	Chemical structure of $^{99\text{m}}\text{Tc}$ -Sestamibi	39
Figure (13)	Chemical structure of $^{99\text{m}}\text{Tc}$ -Tetrofosmin	40